Catalyst

Slingshot members are tracking this event:

Top-line results from Esperion's (ESPR) Phase 3 study 1 (1002-040) of bempedoic acid in ASCVD who are inadequately controlled with current lipid-modifying therapies, including maximally tolerated statins expected in Sept 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ESPR

100%
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Bempedoic Acid